-$1.19 EPS Expected for TESARO, Inc. (TSRO) This Quarter

Equities research analysts forecast that TESARO, Inc. (NASDAQ:TSRO) will report earnings per share (EPS) of ($1.19) for the current quarter, according to Zacks. Seven analysts have provided estimates for TESARO’s earnings. The lowest EPS estimate is ($2.57) and the highest is ($0.52). TESARO posted earnings of ($1.98) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 39.9%. The business is scheduled to announce its next quarterly earnings results on Thursday, November 2nd.

On average, analysts expect that TESARO will report full year earnings of ($9.00) per share for the current year, with EPS estimates ranging from ($10.60) to ($8.04). For the next year, analysts expect that the business will report earnings of ($5.07) per share, with EPS estimates ranging from ($7.63) to ($0.57). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover TESARO.

TESARO (NASDAQ:TSRO) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The business had revenue of $29.50 million during the quarter, compared to analyst estimates of $18.61 million. During the same period in the previous year, the company earned ($1.28) EPS. TESARO’s revenue was down 17.6% on a year-over-year basis.

Several brokerages have recently commented on TSRO. Royal Bank Of Canada started coverage on shares of TESARO in a research note on Thursday, September 14th. They set a “sector perform” rating and a $120.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and issued a $160.00 price objective on shares of TESARO in a research note on Monday, September 11th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $199.00 price objective on shares of TESARO in a report on Sunday, September 10th. Citigroup Inc. reiterated a “buy” rating and issued a $216.00 price objective on shares of TESARO in a report on Monday, September 11th. Finally, Cann reissued a “buy” rating and set a $199.00 target price on shares of TESARO in a research report on Friday, September 8th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. TESARO currently has an average rating of “Buy” and an average target price of $171.42.

In related news, VP Grant C. Bogle sold 14,167 shares of the stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $135.00, for a total value of $1,912,545.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Edward C. English sold 10,862 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the completion of the sale, the vice president now owns 6,258 shares of the company’s stock, valued at approximately $844,329.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 35,692 shares of company stock worth $4,628,976. Insiders own 40.50% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. increased its stake in TESARO by 5.7% during the second quarter. BlackRock Inc. now owns 3,605,247 shares of the biopharmaceutical company’s stock valued at $504,230,000 after acquiring an additional 195,590 shares during the period. Vanguard Group Inc. raised its holdings in TESARO by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,978,236 shares of the biopharmaceutical company’s stock valued at $416,537,000 after acquiring an additional 62,104 shares in the last quarter. State Street Corp lifted its position in shares of TESARO by 17.9% in the 2nd quarter. State Street Corp now owns 1,168,913 shares of the biopharmaceutical company’s stock worth $163,496,000 after acquiring an additional 177,057 shares during the period. BB Biotech AG lifted its position in shares of TESARO by 6.5% in the 2nd quarter. BB Biotech AG now owns 877,990 shares of the biopharmaceutical company’s stock worth $122,796,000 after acquiring an additional 53,408 shares during the period. Finally, Janus Henderson Group PLC bought a new stake in shares of TESARO in the 2nd quarter worth approximately $100,301,000.

TESARO (TSRO) traded up 4.36% during trading on Friday, hitting $129.10. 754,930 shares of the company traded hands. The firm’s market cap is $6.99 billion. The firm has a 50 day moving average of $121.03 and a 200 day moving average of $138.94. TESARO has a one year low of $96.52 and a one year high of $192.94.

ILLEGAL ACTIVITY NOTICE: “-$1.19 EPS Expected for TESARO, Inc. (TSRO) This Quarter” was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://transcriptdaily.com/2017/10/02/1-19-eps-expected-for-tesaro-inc-tsro-this-quarter.html.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Get a free copy of the Zacks research report on TESARO (TSRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply